

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Edward Roydon Jost-Price et al. Confirmation No.: 6397
Serial No.: 10/777,518 Art Unit: 1617
Filed: February 12, 2004 Examiner: Jennifer M. Kim
Customer No.: 21559
Title: COMBINATION THERAPY FOR THE TREATMENT OF
IMMUNOINFLAMMATORY DISORDERS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO RESTRICTION REQUIREMENT


In reply to the Restriction Requirement that was mailed in connection with the above-captioned case on July 3, 2007, Applicants elect group I, claims 1-29 and 57-60, without traverse. In addition, Applicants elect the non-steroidal immunophilin-dependent immunosuppressant (NsIDI) species of cyclosporin A, the NsIDI enhancer species of sertraline, and the third agent species of epinephrine. Claims that read on the elected species are claims 1-3, 6, 7, 15, 22, 28, 29, and 57-60. This election is made without traverse.

Enclosed is a petition to extend the period for replying for four months, to and including December 3, 2007. If there are any additional charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

11/9/07



Michael J. Belliveau, Ph.D.
Reg. No. 52, 608

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045